Fexofenadine microcapsules and compositions containing them
Abstract
one. A pharmaceutical composition comprising microcapsules selected from taste-masked immediate-release microcapsules or co-granulated taste-masked immediate-release microcapsules and mixtures thereof, wherein said microcapsules contain fexofenadine and a water-insoluble polymer coating. 2. The pharmaceutical composition of claim 1, wherein said microcapsules are co-granulated, immediate-release, microcapsules with a masked taste. The pharmaceutical composition according to claims 1 and 2, wherein said fexofenadine is fexofenadine hydrochloride. 4. The pharmaceutical composition according to claim 1, wherein said water-insoluble polymer is selected from the group consisting of ethyl cellulose, polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, ammonium-methacrylate copolymers and mixtures thereof. The pharmaceutical composition according to claim 1, wherein the weight of the water-insoluble polymer of said microcapsules is from about 2% to about 40%. The pharmaceutical composition according to claim 3, wherein said composition releases at least about 60% of said fexofenadine hydrochloride in 15 minutes in a liquid with a pH of 6.8 according to the 2nd edition of the Japanese Pharmacopoeia. The pharmaceutical composition of claim 1, wherein said microcapsules further comprise a surfactant. The pharmaceutical composition according to claim 7, wherein said microcapsules further comprise a glidant or tackifier. The pharmaceutical composition according to claim 1, additionally containing at least one inactive ingredient,
Term
No projected expiry on record.
- Priority
- Filed
- Published
- Today
23 claims: 3 independent, 20 dependent
- 1A pharmaceutical composition comprising the microcapsules, selected from immediate release microcapsules taste masked granulated jointly or immediate release microcapsules taste-masked and mixtures thereof, wherein said microcapsules contain fexofenadine and water-insoluble polymeric coating. 1. Фармацевтическая композиция, содержащая микрокапсулы, выбранные из микрокапсул немедленного высвобождения с замаскированным вкусом или совместно гранулированных микрокапсул немедленного высвобождения с замаскированным вкусом и их смесей, где указанные микрокапсулы содержат фексофенадин и нерастворимое в воде полимерное покрытие.
- 17A process for preparing an immediate release pharmaceutical composition with a taste-masked form of a sachet, comprising the following steps:(a) dissolving the water insoluble polymer in an organic solvent;(B) suspending the Fexofenadine in said organic solvent;(C) coating said water-insoluble polymer to said fexofenadine using phase separation;(D) separating said microcapsules from said organic solvent;(E) optionally wetting the microcapsules;(F) granulating together the microcapsules with at least one inactive ingredient;(G) separate granulation of at least one inactive ingredient;h) blending the joint granulate obtained in step (f), along with a granular inactive ingredient obtained in step (g);(I) filling a mixture of bulk phase (h) in a sachet. 17. Способ получения фармацевтической композиции немедленного высвобождения с замаскированным вкусом в форме саше, включающий следующие этапы: (а) растворения нерастворимого в воде полимера в органическом растворителе;(b) суспендирования фексофенадина в указанном органическом растворителе;(с) нанесения покрытия указанного нерастворимого в воде полимера на указанный фексофенадин помощью разделения фаз;(d) отделение указанных микрокапсул от указанного органического растворителя;(е) необязательного увлажнения микрокапсул;(f) совместной грануляции микрокапсул по меньшей мере с одним неактивным ингредиентом;(g) отдельной грануляции по меньшей мере одного неактивного ингредиента;h) смешивания совместного гранулята, полученного на этапе (f), вместе с гранулированным неактивным ингредиентом, полученным на этапе (g);(i) фасовки нефасованной смеси этапа (h) в саше.
- 18A method of treating a condition associated with inflammation in a subject, comprising administering to an individual in need thereof a pharmaceutical composition comprising an immediate release microcapsules taste masked granulated jointly or immediate release microcapsules taste-masked, wherein said microcapsules contain fexofenadine and insoluble in water polymer coating. 18. Способ лечения состояния, связанного с воспалением, у индивидуума, включающий введение индивидууму, нуждающемуся в этом, фармацевтической композиции, содержащей микрокапсулы немедленного высвобождения с замаскированным вкусом или совместно гранулированные микрокапсулы немедленного высвобождения с замаскированным вкусом, где указанные микрокапсулы содержат фексофенадин и нерастворимое в воде полимерное покрытие.
Independent claims3
41 members in 20 offices
Priority claims11
| Document | Office | Kind | Date |
|---|---|---|---|
| 26582309 | United States of America | P | |
| 61265823 | United States of America | – | |
| 35457510 | United States of America | P | |
| 61354575 | United States of America | – | |
| 2010003196 | International Bureau of the World Intellectual Property Organization (WIPO) | W | |
| 61265823 | – | – | – |
| 61354575 | – | – | – |
| IB2010003196 | – | – | – |
| US20090265823P | – | – | – |
| US20100354575P | – | – | – |
| WO2010IB03196 | – | – | – |
Members41
| Document | Office | Kind | |
|---|---|---|---|
| UY33076A | Uruguay | A | |
| CA2782285A1 | Canada | A1 | |
| WO2011067667A2 | World Intellectual Property Organization (WIPO) | A2 | |
| TW201127421A | Taiwan Province of China | A | |
| US2011250281A1 | United States of America | A1 | |
| AR079248A1 | Argentina | A1 | |
| WO2011067667A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2010325746A1 | Australia | A1 | |
| CL2012001451A1 | Chile | A1 | |
| MX2012006240A | Mexico | A | |
| EP2506836A2 | European Patent Office (EPO) | A2 | |
| CO6541583A2 | Colombia | A2 | |
| KR20120136346A | Republic of Korea | A | |
| JP2013507433A | Japan | A | |
| CN102958515A | China | A | |
| ZA201203983B | South Africa | B | |
| JP5309262B2 | Japan | B2 | |
| US8580313B2 | United States of America | B2 | |
| JP2013231051A | Japan | A | |
| RU2012124262AThis record | Russian Federation | A | |
| US2014141091A1 | United States of America | A1 | |
| NZ600256A | New Zealand | A | |
| JP5519839B2 | Japan | B2 | |
| JP2014139231A | Japan | A | |
| TWI471146B | Taiwan Province of China | B | |
| SG10201407965XA | Singapore | A | |
| JP5732572B2 | Japan | B2 | |
| RU2563623C2 | Russian Federation | C2 | |
| US9233105B2 | United States of America | B2 | |
| AU2010325746B2 | Australia | B2 | |
| US2016081991A1 | United States of America | A1 | |
| IL220085A | Israel | A | |
| KR101765357B1 | Republic of Korea | B1 | |
| EP2506836B1 | European Patent Office (EPO) | B1 | |
| ES2668203T3 | Spain | T3 | |
| CN108159019A | China | A | |
| US10166220B2 | United States of America | B2 | |
| US2019076414A1 | United States of America | A1 | |
| US10729682B2 | United States of America | B2 | |
| US2020316042A1 | United States of America | A1 | |
| US2021137899A1 | United States of America | A1 |
3 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| The patent is invalid due to non-payment of feesMM4A | MM4A | |
| Official registration of the transfer of exclusive rightPC41 | PC41 | |
| Correction of name of patent ownerPD4A | PD4A |
Numbers
- Publication
- 2012124262
- Publication, DOCDB
- 2012124262
- Publication, EPODOC
- RU2012124262
- Application
- 201212426215
- Application, DOCDB
- 2012124262
- Application, EPODOC
- RU20120124262
Titles2
- English
- MICROCAPSULES fexofenadine and compositions containing them
- Russian
- ???????????? ????????????? ? ?????????? ?? ??????????
Classification
- CPC, 12
- A61K9/5047
- A61K31/445
- A61K9/5026
- A61K9/5042
- A61K9/5089
- A61P11/02
- A61P17/00
- A61P17/04
- A61P29/00
- A61P37/00
- A61P37/08
- A61P43/00